You just read:

MEI Pharma Announces Pre-Specified Response Rate Exceeded in Dose-Escalation Study of ME-401 in Chronic Lymphocytic Leukemia and Follicular Lymphoma

News provided by

MEI Pharma, Inc.

May 31, 2017, 08:30 ET